✦ LIBER ✦

A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease

✍ Scribed by Stephen Hanauer; Milan Lukáš; Donald MacIntosh; Paul Rutgeerts; William Sandborn; Paul Pollack

Book ID: 119757860
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 45 KB
Volume: 127
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2004.05.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, placebo-controlled trial o

A randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with moderate to severe Crohn's disease

✍ William J. Sandborn; Brian Feagan; Graham Radford-Smith; Agota Kovacs; Robert En 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Secukinumab, a human anti-IL-17A monoclo

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

✍ Hueber, W.; Sands, B. E.; Lewitzky, S.; Vandemeulebroecke, M.; Reinisch, W.; Hig 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 304 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease

✍ J. C. MANSFIELD; M. PARKES; A. B. HAWTHORNE; A. FORBES; C. S. J. PROBERT; R.C. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 563 KB

Adalimumab for the treatment of patients

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial

✍ Philip J. Mease; Dafna D. Gladman; Christopher T. Ritchlin; Eric M. Ruderman; Se 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohn's disease

✍ B. G. Feagan; W. J. Sandborn; J. P. Baker; F. Cominelli; L. R. Sutherland; C. O 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 331 KB